BIO-Windhover and Windhover Pharmaceutical Strategic Outlook

Feb. 23, 2010-Feb. 25, 2010
Grand Hyatt
New York, NY
www.biowindhover.com

Description:

Option Based Deal-Making: Structures for Bull and Bear Markets

Ben Bonifant, head of our Business Development practice, will moderate a panel discussion titled "Option Based Deal-Making: Structures for Bull and Bear Markets." Additional panelists include executives Sanofi-Aventis, BiPar, GSK, Novartis Venture Fund, and Avila Therapeutics.

Abstract:

Option Based Deal-Making: Structures for Bull and Bear Markets

Weak financial markets have created an option-based dealmaking bonanza, with pharma buyers calling the shots and limiting risk—and cost—to the maximum. Other forms of contingency-based deals, such as earn-out acquisitions, have also gained traction in a buyer’s market. This panel examines how long the trend can continue, and in particular whether recovering public markets will weaken—or even shut down-- option- and contingency-based dealmaking. 

Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance (Moderator)  

Sanofi’s Perspective on Dealmaking
Philippe Goupit, Vice President Corporate Licenses, Sanofi Aventis

Lessons Learned from the Sanofi-Aventis/BiPar Acquisition 
Hoyoung Huh, MD, PhD, CEO, BiPar Sciences, a Sanofi-Aventis company 

The Model Du Jour For GlaxoSmithKline 
Shelagh Wilson, PhD, Vice President, Head of European CEEDD, GlaxoSmithKline 

The Novartis Option Fund: A Model For Other Corporate Venture Investors?
Lauren Silverman, PhD, Managing Director, Novartis Venture Fund, Novartis 

How Biotechs Can Make Option-based Deals Work
Katrine Bosley, CEO, Avila Therapeutics

View Entire Event Calendar

Don't Miss